<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02500940</url>
  </required_header>
  <id_info>
    <org_study_id>CF15113A</org_study_id>
    <nct_id>NCT02500940</nct_id>
  </id_info>
  <brief_title>Comparison the Effects of Different Neoadjuvant Chemotherapy Regimen on Acute Toxicity, Tumor Response, and Survival in Patients With Advanced Nasopharyngeal Carcinoma</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taichung Veterans General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Taichung Veterans General Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the impact of different neoadjuvant chemotherapy
      schedules of cisplatin and 5-FU on acute toxicity, tumor response, and long-term survival in
      patients with advanced nasopharyngeal carcinoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Control group: Neoadjuvant chemotherapy with tri-weekly PF × 3 cycles (cisplatin 100 mg/m2,
      day 1, followed by 5-FU 1000 mg/m2/d, days 1-4 continuous iv infusion, repeated every 3
      weeks) + IMRT ≧ 70 Gy/35 fractions

      Test group: Neoadjuvant chemotherapy with weekly P-FL × 10 weeks (cisplatin 60 mg/m2 at days
      1, 15, 29, 43, 57; alternatively with 5-FU 2500 mg/m2 + Leucovorin 250 mg/m2 at days 8, 22,
      36, 50, 64) + IMRT ≧ 70 Gy/35 fractions
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response by RECIST version 1.1</measure>
    <time_frame>5 years</time_frame>
    <description>According to RECIST version 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity by CTCAE deifnition</measure>
    <time_frame>6 months</time_frame>
    <description>According to CTCAE deifnition</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant chemotherapy with tri-weekly cisplatin plus fluorouracil × 3 cycles (cisplatin 100 mg/m2, day 1, followed by fluorouracil 1000 mg/m2/d, days 1-4 continuous iv infusion, repeated every 3 weeks) + Intensity-Modulated Radiation Therapy ≧ 70 Gy/35 fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neoadjuvant chemotherapy with weekly cisplatin, fluorouracil and leucovorin × 10 weeks (cisplatin 60 mg/m2 at days 1, 15, 29, 43, 57; alternatively with fluorouracil 2500 mg/m2 + leucovorin 250 mg/m2 at days 8, 22, 36, 50, 64) + Intensity-Modulated Radiation Therapy ≧ 70 Gy/35 fractions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Neoadjuvant chemotherapy regimen with cisplatin</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Test group</arm_group_label>
    <other_name>CDDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Neoadjuvant chemotherapy regimen with Fluorouracil</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Test group</arm_group_label>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>Intensity-Modulated Radiation Therapy</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Test group</arm_group_label>
    <other_name>IMRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Neoadjuvant chemotherapy regimen with Leucovorin</description>
    <arm_group_label>Test group</arm_group_label>
    <other_name>Calcium folinate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histological proven NPC.

          2. 2010 AJCC stage II-IVB.

          3. Age ≧ 20 years old.

          4. Performance status of ECOG ≦ 2.

          5. Adequate liver, renal, and bone marrow functions 5-1 Serum total bilirubin level ≦ 2.5
             mg/dl. 5-2 Serum creatinine ≦ 1.6 mg/dl or calculated CCr ≧ 60 cc/min. 5-3 WBC ≧
             3,000/ul 5-4 Platelet count ≧ 100,000/ul

          6. Signed informed consent.

        Exclusion Criteria:

          1. Presence of distant metastasis.

          2. Previous radiotherapy or chemotherapy.

          3. History of a malignancy except those treated with curative intent for skin cancer
             (other than melanoma), in situ cervical cancer, ductal carcinoma in situ (DCIS) of the
             breast.

          4. Severe cardiopulmonary diseases (unstable angina and/or congestive heart failure or
             peripheral vascular disease requiring hospitalization within the last 12 months;
             chronic obstructive pulmonary disease exacerbation or other respiratory illness
             requiring hospitalization) or clinically significant psychiatric disorders.

          5. Female patients who are pregnant or lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Jin-Ching, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Taichung Veterans General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lin Jin-Ching, Ph.D</last_name>
    <phone>+886-4-23592525</phone>
    <phone_ext>5613</phone_ext>
    <email>jclin@vghtc.gov.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taichung Vaterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Ching Lin, Professor</last_name>
      <phone>+886 4 23592525</phone>
      <phone_ext>5613</phone_ext>
      <email>jclin@vghtc.gov.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2015</study_first_submitted>
  <study_first_submitted_qc>July 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2015</study_first_posted>
  <last_update_submitted>July 14, 2015</last_update_submitted>
  <last_update_submitted_qc>July 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

